Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy

Cancer Chemotherapy and Pharmacology - Tập 11 - Trang S47-S50 - 1983
Yoshizo Nakagami1, Tatsuo Minowa1, Kazuhiko Tozuka1, Yasunori Hiraoka1, Hansui Chin1
1Department of Urology, First Hospital of Nippon Medical School, Tokyo, Japan

Tóm tắt

The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%–80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy, followed by administration of PSK and carboquone (CQ) in small amounts as maintenance therapy continuously for about 3 years, and the course was observed. In both consolidation and maintenance groups various non-specific immunoparameters were superior in groups receiving combined immunotherapeutic agents. Thus, the use of immunotherapeutic agents in combination with chemotherapeutic agents was considered to be effective. The 3-year recurrence rate was only 8% in the multidisciplinary treatment group, while that in the non-multidisciplinary treatment group was 61%. This approach, especially with chemoimmunotherapy (ADM and OK-432) as a consolidation therapeutic mode, is therefore considered to be useful for the prevention of recurrence.

Tài liệu tham khảo

Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36: 729–747 Cohen J (1969) Statistical power analysis for the behavioral sciences. Academic Press, New York Dekernion JB, Skinner DG (1978) Epidemiology, diagnosis, and staging of bladder cancer. In: Skinner DG (ed) Genitourinary cancer. Saunders, Philadelphia London Toronto, pp 213–231 Gehan EA, Freireich EJ (1974) Non-randomized controls in cancer clinical trials. N Engl J Med 290: 198–203 Hoshino T, Uchida A, et al (1976) Immunotherapy of cancer with immunostimulants. Jpn J Clin Immunol 8: 1105–1114 Karnofsky DA (1961) Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 2: 709–712 Mathé G, et al (1969) Active immunotherapy for acute lymphoblastic leukemia. Lancet I: 697 Morton DL, et al (1974) BCG immunotherapy of malignant melanoma. Summary of seven year's experience. Ann Surg 180: 635 Nakagami Y, et al (1978a) Adjuvant immunotherapy with antitumor Str. pyogenes preparation in urogenital carcinoma. J Nippon Med Sch 45: 284–286 Nakagami Y, et al (1978b) Adjuvant immunotherapy with antitumor Str. pyogenes preparation in urogenital carcinoma. (Abstract) XIIth International Congress of Cancer in Buenos Aires, Workshop #28 No. 2, 71 Nakagami Y, et al (1979) Adjuvant immunotherapy with antitumor Str. pyogenes preparation (immunopotentiator OK-432) in urogenital carcinoma. Acta Urol Jap 25: 133–141 Niijima T (1978) Intravesical therapy with adriamycin and new trends in the diagnostics and therapy of superficial urinary bladder tumours. WHO center meeting records, pp 37–44 Persky L, Krush ED, Soloway M (1978) Urotherlial tumors. In: Devine CJ Jr (ed) Urology in practice. Little, Brown, Boston, pp 653–690 Turner AG, Durrant KR, Malpas JS (1979) A trial of bleomycin versus adriamycin in advanced carcinoma of the bladder. Br J Urol 51: 121–124 Union Internationale Contre le Cancer (1978) TNM classification of malignant tumors. UICC, Geneve, pp 113–117 Wallace DM, Bloom HJG (1976) The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (First report). Br J Urol 48: 587–594 Weinstein SH, Schmidt JD (1976) Doxorubicin chemotherapy in advanced transitional cell carcinoma. Urology 8: 336–341 Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MP, Krakoff IH (1977) Adriamycin in advanced urinary tract cancer. Cancer 39: 279–285 Yata J (1978) Cells involved in immune responses and their rules. Jpn J Dermatol [B] 88: 607–613